Ramón
García Sanz
Profesor Titular de Universidad
María Belén
Vidriales Vicente
Profesora Asociada CC. Salud
Publicaciones en las que colabora con María Belén Vidriales Vicente (35)
2024
-
Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient
Biomedicines, Vol. 12, Núm. 1
2023
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
2020
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2018
-
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
Blood cancer journal, Vol. 8, Núm. 12, pp. 117
2017
-
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
Leukemia, Vol. 31, Núm. 10, pp. 2094-2103
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
-
The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*
Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152
2016
-
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance
Blood, Vol. 127, Núm. 15, pp. 1896-1906
2015
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
-
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Haematologica, Vol. 100, Núm. 2, pp. e53-e55
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Blood, Vol. 124, Núm. 8, pp. 1300-1303
-
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification
Leukemia, Vol. 28, Núm. 1, pp. 166-173
2013
-
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Haematologica, Vol. 98, Núm. 1, pp. 79-86
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598
2011
-
Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry
Clinical Lymphoma, Myeloma and Leukemia
-
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
Blood, Vol. 118, Núm. 17, pp. 4547-4553
-
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
Clinical lymphoma, myeloma & leukemia, Vol. 11, Núm. 1, pp. 168-171